The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Two cycles of carboplatin as adjuvant therapy in stage I seminoma: 8-year experience by the Hellenic Co-operative Oncology Group (HECOG).
Konstantinos Koutsoukos
No relevant relationships to disclose
Michael Liontos
No relevant relationships to disclose
Maria Lykka
No relevant relationships to disclose
Georgios Rigakos
No relevant relationships to disclose
Anna Andreadou
No relevant relationships to disclose
Eleni Efstathiou
No relevant relationships to disclose
Angelos Koutras
No relevant relationships to disclose
Athanasios Papatsoris
No relevant relationships to disclose
Michael Chrisofos
No relevant relationships to disclose
Kostas Stravodimos
No relevant relationships to disclose
Ioanis Adamakis
No relevant relationships to disclose
Christos Alamanis
No relevant relationships to disclose
Vasilios Karavasilis
No relevant relationships to disclose
Thomas Makatsoris
No relevant relationships to disclose
Eleni P. Galani
No relevant relationships to disclose
George Klouvas
No relevant relationships to disclose
Paris A. Kosmidis
No relevant relationships to disclose
George Fountzilas
No relevant relationships to disclose
Meletios A. Dimopoulos
No relevant relationships to disclose
Aristotelis Bamias
No relevant relationships to disclose